Posaconazole : a pharmaceutical review

Abstract EN

Posaconazole (Noxafil), a second generation 1,2,4-triazole antifungal antibiotic, has been approved by the USFDA for the prophylaxis of invasive Candida spp.

and Aspergillus spp.

infections and for oropharyngeal candidiasis, comprising oropharyngeal candidiasis that is unmanageable to Itraconazole and/or Fluconazole.

This lipophilic drug is marketed as a suspension, a sustained release tablet, and as an injection.

Many new pharmaceutical findings have been published regarding its prodrug, dosage forms, nanoparticles, polymorphs and clinical trials.

This review article briefly discusses the various marketed dosage forms, chemistry, pharmacology, spectrum of activity, new compositions, important patent literature and ongoing clinical trials related to Posaconazole.

Till the date of this manuscript, there is no published review article that provides information about the pharmaceutical aspects of Posaconazole.

This article will be useful for pharmacists, medical and paramedical professionals seeking to know better about the pharmaceutical aspects of Posaconazole